Major Depressive Disorder (DSM-V) – Epidemiology – Epidemiology – Major Depressive Disorder (DSM V) – Mature Markets
Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report the prevalence of MDD (DSM-V) for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s MDD (DSM-V) forecast will answer the following questions:
- Of all people with MDD (DSM-V), how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with MDD (DSM-V), how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MDD (DSM-V) over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Clarivate Epidemiology forecasts the following MDD (DSM-V) patient populations:
- Total lifetime prevalent cases.
- Total 12-month prevalent cases.
Note: Coverage may vary by country.
Table of contents
- Major Depressive Disorder (DSM-V) - Epidemiology - Epidemiology - Major Depressive Disorder (DSM V) - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of major depressive disorder [DSM-V])
- Total lifetime prevalence of MDD
- Total 12-month prevalent cases of MDD
- Diagnosed lifetime prevalent cases of MDD
- Diagnosed lifetime drug-treated prevalent cases of MDD
- Risk / protective factors applied to disease forecast models
- Reference materials
Mariam Sophia, M.P.H., Epidemiologist. Prior to studying epidemiology, she had a private clinical practice and later worked as a tutor at Manipal College of Dental Sciences. She has experience working in COVID-19 care centers and in Tele ICU. She holds an M.P.H. from India’s Manipal University, where she specialized in epidemiology. Her research thesis assessed the nutritional status of tribal children less than five years old. She has interned in the government-run tuberculosis program (RNTCP).
Aishwarya S. Ambat, M.P.H., Epidemiologist , Epidemiology. She received her M.P.H. from the Manipal Academy of Higher Education in India and holds a bachelor’s degree in physiotherapy. Her areas of interest are rheumatic disease and cancer epidemiology.